A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Mavoglurant (Primary)
- Indications Cocaine abuse
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 29 Aug 2018 Planned End Date changed from 11 Mar 2019 to 8 Jan 2020.
- 29 Aug 2018 Planned primary completion date changed from 11 Mar 2019 to 8 Jan 2020.